Russell Investments Group Ltd. Has $18.07 Million Position in Natera, Inc. $NTRA

Key Points

• Russell Investments Group Ltd. increased its stake in Natera, Inc. by 309.8% in the 1st quarter, owning 127,767 shares valued at $18,068,000.
• Natera's recent quarterly earnings report revealed a loss of ($0.74) per share, missing estimates while generating $546.60 million in revenue, which exceeds analyst expectations.
• Despite a mixed earnings outcome, analyst ratings are predominantly positive with 17 buy ratings and a target price increase from various firms, averaging around $193.19.

Russell Investments Group Ltd. lifted its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 309.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 127,767 shares of the medical research company's stock after purchasing an additional 96,592 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.09% of Natera worth $18,068,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. Fulton Bank N.A. grew its holdings in shares of Natera by 2.0% during the 1st quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock worth $516,000 after purchasing an additional 71 shares in the last quarter. QRG Capital Management Inc. raised its position in Natera by 1.5% in the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock worth $766,000 after purchasing an additional 81 shares in the last quarter. Earned Wealth Advisors LLC raised its position in Natera by 5.0% in the first quarter. Earned Wealth Advisors LLC now owns 1,737 shares of the medical research company's stock worth $246,000 after purchasing an additional 82 shares in the last quarter. Bridges Investment Management Inc. raised its position in Natera by 5.5% in the first quarter. Bridges Investment Management Inc. now owns 1,676 shares of the medical research company's stock worth $237,000 after purchasing an additional 87 shares in the last quarter. Finally, Colonial Trust Co SC raised its position in Natera by 7.8% in the fourth quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company's stock worth $210,000 after purchasing an additional 96 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several recent analyst reports. Royal Bank Of Canada boosted their target price on shares of Natera from $251.00 to $255.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. UBS Group boosted their target price on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Piper Sandler restated an "overweight" rating and issued a $220.00 target price (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. Evercore ISI upgraded shares of Natera to a "strong-buy" rating and set a $170.00 target price on the stock in a research note on Monday, July 28th. Finally, Cowen reaffirmed a "buy" rating on shares of Natera in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company. According to data from MarketBeat.com, Natera presently has a consensus rating of "Buy" and a consensus price target of $193.19.

Natera Stock Up 2.5%

NTRA stock traded up $3.98 during midday trading on Friday, reaching $165.93. The stock had a trading volume of 246,492 shares, compared to its average volume of 1,511,262. The business has a fifty day simple moving average of $154.84 and a two-hundred day simple moving average of $154.38. The firm has a market cap of $22.77 billion, a price-to-earnings ratio of -86.78 and a beta of 1.76. Natera, Inc. has a twelve month low of $110.57 and a twelve month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business's revenue for the quarter was up 32.2% compared to the same quarter last year. During the same period last year, the company earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. On average, equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Michael Burkes Brophy sold 3,045 shares of the business's stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total transaction of $418,383.00. Following the completion of the transaction, the chief financial officer owned 65,430 shares in the company, valued at approximately $8,990,082. The trade was a 4.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Solomon Moshkevich sold 3,000 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $157.07, for a total transaction of $471,210.00. Following the transaction, the insider owned 133,205 shares of the company's stock, valued at approximately $20,922,509.35. This represents a 2.20% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 61,792 shares of company stock worth $9,227,972. Company insiders own 5.63% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.